Pegaptanib for neovascular age-related macular degeneration

Maberley D
Record ID 32006000008
English, French
Authors' objectives:

The aim of this report is to summarize the available information on the use of pegaptanib (Trade Mark Macugen, manufactured by EyeTech and Pfizer Pharmaceuticals in the US and by Pfizer outside the US) for the treatment of neovascular (wet) age-related macular degeneration.

Authors' recommendations: In two concurrent, high-quality studies using identical research methods, pegaptanib demonstrated a therapeutic advantage over placebo for the prevention of vision loss due to neovascular age-related macular degeneration. As pegaptanib is injected into the eye every six weeks, there is a risk of endophthalmitis (intraoccular infection), lens damage (if accidentally penetrated), and retinal detachment. Systemic side effects have not been associated with pegaptanib.
Authors' methods: Overview
Project Status: Completed
URL for project:
Year Published: 2005
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Choroidal Neovascularization
  • Macular Degeneration
  • Oligonucleotides
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.